United States Food and Drug Administration-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2021

  1. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

  2. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 27, Núm. 10, pp. 807-816

2014

  1. Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

    American Journal of Hematology

2010

  1. Human peripheral blood B-Cell compartments: A crossroad in B-cell traffic

    Cytometry Part B - Clinical Cytometry, Vol. 78, Núm. SUPPL. 1

2005

  1. Assessment of the value of confirming responses in clinical trials in oncology

    European Journal of Cancer, Vol. 41, Núm. 11, pp. 1528-1532